However, when it is no longer confined to the primary site, these treatments are often not successful, with nearly half of the patients showing a rise in the PCa biomarker, prostate-specific antigen (PSA), thus requiring further therapy [2]. Here, KLK3 is linked to posterior cortical atrophy.